{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:07:05Z","timestamp":1781089625354,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218646","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:29:14Z","timestamp":1780154954000},"page":"218646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression"],"prefix":"10.1016","volume":"655","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-4469","authenticated-orcid":false,"given":"Abhishek","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5499-0464","authenticated-orcid":false,"given":"Avinandan","family":"Bhoumick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhojit","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhasis","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7976-791X","authenticated-orcid":false,"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosenjit","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218646_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218646_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2011.00098","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218646_bib4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00018-020-03696-4","article-title":"Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy","volume":"78","author":"Lan","year":"2021","journal-title":"Cell. Mol. Life Sci. C."},{"key":"10.1016\/j.canlet.2026.218646_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/ol.2011.291","article-title":"Protease-activated receptors in cancer: a systematic review","volume":"2","author":"Han","year":"2011","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218646_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134932","article-title":"Protease activated receptors 1 and 2 correlate differently with breast cancer aggressiveness depending on tumor ER status","volume":"10","author":"Lidfeldt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218646_bib7","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1074\/jbc.RA119.008619","article-title":"Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition","volume":"294","author":"Das","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218646_bib8","doi-asserted-by":"crossref","first-page":"13688","DOI":"10.1074\/jbc.M116.764670","article-title":"Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to -catenin accumulation via the AKT\/GSK3 pathway and contributes to breast cancer progression","volume":"292","author":"Roy","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218646_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.biopha.2018.05.155","article-title":"Matrix metalloproteinase-2: a key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling","volume":"105","author":"Das","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218646_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051524","article-title":"The tissue factor pathway in cancer: overview and role of heparan sulfate proteoglycans","volume":"15","author":"Hassan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218646_bib11","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/j.1538-7836.2012.04917.x","article-title":"Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa","volume":"10","author":"Clark","year":"2012","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.canlet.2026.218646_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11","author":"Krishnaswamy","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.canlet.2026.218646_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118031","article-title":"The role of thrombin in the paradoxical interplay of cancer metastasis and the vascular system: a driving dynamic","volume":"186","author":"Bayrak","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218646_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2006.10.002","article-title":"Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype","volume":"10","author":"Nierodzik","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/mc.23398","article-title":"Immunomodulatory role of thrombin in cancer progression","volume":"61","author":"Alexander","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2026.218646_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4860","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2","volume":"12","author":"Metelli","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218646_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12935-025-03877-w","article-title":"The role of platelets in tumor immune evasion and metastasis: mechanisms and therapeutic implications","volume":"25","author":"Gan","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218646_bib18","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1074\/jbc.M704855200","article-title":"Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and \u03b21-integrin on the cell surface","volume":"283","author":"Radjabi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218646_bib19","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.thromres.2017.12.020","article-title":"Mechanisms coupling thrombin to metastasis and tumorigenesis","volume":"164","author":"Remiker","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.canlet.2026.218646_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2006.10.002","article-title":"Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype","volume":"10","author":"Nierodzik","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib21","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-09-0187","article-title":"Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt-survival pathways in breast cancer cells and suppresses tumor survival and metastasis","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111822","article-title":"Inhibition of cancer cell migration and invasion in vitro by recombinant tyrosine-sulfated haemathrin, A thrombin inhibitor","volume":"25","author":"Jo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218646_bib23","first-page":"63","article-title":"Role of thrombin in angiogenesis and tumor progression","volume":"30","author":"Tsopanoglou","year":"2004"},{"key":"10.1016\/j.canlet.2026.218646_bib24","doi-asserted-by":"crossref","first-page":"23969","DOI":"10.1074\/jbc.274.34.23969","article-title":"On the mechanism of thrombin-induced angiogenesis","volume":"274","author":"Tsopanoglou","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218646_bib25","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1186\/1471-2407-7-S1-A10","article-title":"Signaling induced by PAR1 on breast cancer cell lines is correlating with its invasive potential","volume":"7","author":"Cancino","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218646_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-7-47","article-title":"PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study","volume":"7","author":"Hern\u00e1ndez","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218646_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","article-title":"PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells","volume":"120","author":"Boire","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad7993","article-title":"Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation","volume":"352","author":"Rialdi","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.canlet.2026.218646_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218646_bib30","article-title":"Targeting DNA topoisomerase I for the treatment of cancer: past, present and future","author":"Venkatachalam","year":"2025","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218646_bib31","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154499","article-title":"Myeloid cell\u2010specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation","volume":"23","author":"Zhu","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2026.218646_bib33","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.cell.2021.03.051","article-title":"TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation","volume":"184","author":"Ho","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41580-021-00444-9","article-title":"MYC in TOP shape","volume":"23","author":"Zlotorynski","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218646_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-014-0112-7","article-title":"Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction","volume":"33","author":"Wu","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib36","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/0008-5472.CAN-08-0831","article-title":"Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity","volume":"68","author":"Goswami","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/MCB.06321-11","article-title":"Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation","volume":"32","author":"Chaudhry","year":"2012","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218646_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41419-020-03292-1","article-title":"Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore","volume":"12","author":"Cheratta","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218646_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060883","article-title":"Chemotherapeutic drugs inhibiting topoisomerase 1 activity impede cytokine-induced and NF-\u03baB p65-Regulated gene expression","volume":"11","author":"Riedlinger","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218646_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0813055106","article-title":"Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-\u03baB activation and invasive prostate carcinoma","volume":"106","author":"Fernandez-Marcos","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218646_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ccr.2013.05.007","article-title":"Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy","volume":"24","author":"Alvarez","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.toxlet.2013.10.008","article-title":"Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K\/Akt pathway-dependent EMT","volume":"224","author":"Tan","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.canlet.2026.218646_bib43","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1172\/JCI99481","article-title":"Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer","volume":"128","author":"Mabe","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218646_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gde.2016.11.001","article-title":"H3K27 methylation: a promiscuous repressive chromatin mark","volume":"43","author":"Wiles","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218646_bib45","first-page":"1","article-title":"EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218646_bib46","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1073\/pnas.1308953111","article-title":"EZH2 expands breast stem cells through activation of NOTCH1 signaling","volume":"111","author":"Gonzalez","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218646_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104972","article-title":"Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic","volume":"100","author":"Guo","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.canlet.2026.218646_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05955-2","article-title":"P38\u03b1\/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim","volume":"9","author":"Hu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218646_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189157","article-title":"Molecular insights into the role of mixed lineage kinase 3 in cancer hallmarks","volume":"1879","author":"Ke","year":"2024","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218646_bib50","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.204.Supp.241.7","article-title":"Paradoxical role of MLK3-CTLA-4 axis in triple-negative breast cancer and CD8+ T cells","volume":"204","author":"Kumar","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218646_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molcel.2005.08.016","article-title":"Binding and phosphorylation of Par-4 by Akt is essential for cancer cell survival","volume":"20","author":"Goswami","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218646_bib52","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4161\/cbt.7.12.6945","article-title":"Apoptosis and tumor resistance conferred by Par-4","volume":"7","author":"Zhao","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2026.218646_bib53","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/j.1538-7836.2007.02769.x","article-title":"Protease-activated receptor-induced Akt activation - regulation and possible function","volume":"5","author":"Res\u00e9ndiz","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.canlet.2026.218646_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102022","article-title":"Protease-activated receptor 2 induces ROS-mediated inflammation through Akt-mediated NF-\u03baB and FoxO6 modulation during skin photoaging","volume":"44","author":"Bang","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2026.218646_bib55","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-10-2370","article-title":"The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model","volume":"17","author":"Sharma","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6371-0","article-title":"Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study","volume":"19","author":"Tesauro","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218646_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920958354","article-title":"Exploiting DNA repair defects in triple negative breast cancer to improve cell killing","volume":"12","author":"Lee","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218646_bib58","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/13543784.2011.606809","article-title":"Vorapaxar: a novel protease-activated receptor-1 inhibitor","volume":"20","author":"Gurbel","year":"2011","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2026.218646_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123517","article-title":"Pleiotropic effects of the protease-activated receptor 1 (PAR1) inhibitor, Vorapaxar, on atherosclerosis and vascular inflammation","volume":"10","author":"Friebel","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218646_bib60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1568009023333890","article-title":"Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Mathijssen","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2026.218646_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.2011.498","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"Gilbert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218646_bib62","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/sj.onc.1206935","article-title":"Mechanisms of resistance to topoisomerase I-targeting drugs","volume":"22","author":"Rasheed","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218646_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00653-2","article-title":"DNA damage response in breast cancer and its significant role in guiding novel precise therapies","volume":"12","author":"Li","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218646_bib64","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib65","first-page":"15","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast Off. J. Eur. Soc. Mastology"},{"key":"10.1016\/j.canlet.2026.218646_bib66","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218646_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70803","article-title":"Targeting triple-negative breast cancer: resistance mechanisms and therapeutic advancements","volume":"14","author":"Raman","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218646_bib68","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3390\/cancers14174280","article-title":"Challenges for triple negative breast cancer treatment: defeating heterogeneity and cancer stemness","volume":"14","author":"Mahmoud","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218646_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118031","article-title":"The role of thrombin in the paradoxical interplay of cancer metastasis and the vascular system: a driving dynamic","volume":"186","author":"Bayrak","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218646_bib70","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-11-1432","article-title":"PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis","volume":"71","author":"Zigler","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib71","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-18-0106","article-title":"High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling","volume":"24","author":"Hayashi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib72","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218646_bib73","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218646_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218646_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.101035","article-title":"Protease-activated receptor antagonist for reducing cardiovascular events - a review on vorapaxar","volume":"48","author":"Gupta","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.canlet.2026.218646_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40268-016-0158-4","article-title":"Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease","volume":"17","author":"Gryka","year":"2017","journal-title":"Drugs R&D"},{"key":"10.1016\/j.canlet.2026.218646_bib77","article-title":"Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265 2 prior lines of chemotherapy: a phase Ib study","volume":"16","author":"Fan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218646_bib78","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdi227","article-title":"A phase I\/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer","volume":"16","author":"Rea","year":"2005","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218646_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040680","article-title":"Understanding cancer's defense against topoisomerase-active drugs: a comprehensive review","volume":"16","author":"Sharma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218646_bib80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1054\/drup.1999.0102","article-title":"Topoisomerase I inhibitors: selectivity and cellular resistance","volume":"2","author":"Pommier","year":"1999","journal-title":"Drug Resist. Updates"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:37:31Z","timestamp":1781087851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S030438352600409X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218646","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218646"}}